Aspera Biomedicines, Inc.
1 clinical trials · Sponsor
◉ Watch Aspera Biomedicines, Inc.
| Record | Firm | Date |
|---|---|---|
| A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis (NCT07250646) | Aspera Biomedicines, Inc. | 2026-05-21 |
Track Aspera Biomedicines, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.